New CMS Medicare Drug Price Guidance: Navigating Price Negotiations, 340B Drugs, CMPs for Violations
Recording of a 90-minute CLE video webinar with Q&A
This CLE webinar will guide healthcare counsel on the new CMS guidance on the Medicare Drug Price Negotiation Program. The panel will examine the guidance, discussing the drug selection criteria and the negotiation process. The panel will also address other areas of guidance and offer best practices for navigating drug price negotiations.
- American Rescue Plan Act
- Medicaid inflation rebate changes
- Medicare Drug Price Negotiation Program guidance
- Drug selection criteria
- Negotiation process
- Additional guidance
- Negotiations related to 340B drugs
- Issuance of CMPs for violations
- Best practices for navigating drug price negotiations
- What's on deck: Center for Medicare and Medicaid Innovation Models
The panel will review these and other key issues:
- What drug selection criteria does the new CMS guidance set forth?
- How will this development affect drug pricing going forward?
- How will drug negotiations change drug pricing strategies?
Mimi Moll Alexandre
McDermott Will & Emery
Ms. Alexandre counsels clients across the healthcare industry with a particular focus on entities in the managed care... | Read More
Ms. Alexandre counsels clients across the healthcare industry with a particular focus on entities in the managed care arena. She routinely works with health plans, health maintenance organizations, private equity funds and vendors, helping them navigate complex regulatory schemes and facilitate business objectives.Close
Steven J. Schnelle
McDermott Will & Emery
Mr. Schnelle delivers business-focused legal solutions to investors and business operators in the US healthcare market.... | Read More
Mr. Schnelle delivers business-focused legal solutions to investors and business operators in the US healthcare market. He is particularly focused on legal matters involving healthcare providers and suppliers, equipment and device manufacturers and suppliers, pharmacies, health tech and digital solutions providers, and market innovators. Mr. Schnelle regularly assists clients with matters involving government and commercial payor audits and investigations, administrative appeals and investment strategies for assets in dispute with government or commercial payors.Close